dc.contributor.author | Lee, K. H. | |
dc.contributor.author | Kato, T. | |
dc.contributor.author | Macpherson, E. | |
dc.contributor.author | Newton, M. | |
dc.contributor.author | Thiyagarajah, P. | |
dc.contributor.author | Antonia, S. | |
dc.contributor.author | Reck, M. | |
dc.contributor.author | de Wit, M. | |
dc.contributor.author | Spigel, D. | |
dc.contributor.author | Faivre-Finn, C. | |
dc.contributor.author | Gray, J. | |
dc.contributor.author | Vicente, D. | |
dc.contributor.author | Planchard, D. | |
dc.contributor.author | Paz-Ares, L. | |
dc.contributor.author | Vansteenkiste, J. | |
dc.contributor.author | Garassino, M. | |
dc.contributor.author | Hui, R. | |
dc.contributor.author | Quantin, X. | |
dc.contributor.author | Rimner, A. | |
dc.contributor.author | Wu, Y. -L. | |
dc.contributor.author | ÖZGÜROĞLU, Mustafa | |
dc.date.accessioned | 2021-12-10T11:21:15Z | |
dc.date.available | 2021-12-10T11:21:15Z | |
dc.identifier.citation | de Wit M., Spigel D., Faivre-Finn C., Gray J., Vicente D., Planchard D., Paz-Ares L., Vansteenkiste J., Garassino M., Hui R., et al., "5-Year Survival Data of Durvalumab after Chemoradiotherapy for unresectable Stage III NSCLC - an Update from the PACIFIC Study", STRAHLENTHERAPIE UND ONKOLOGIE, cilt.197, 2021 | |
dc.identifier.issn | 0179-7158 | |
dc.identifier.other | av_7824b29e-167d-4851-b577-d01a94a1ee1a | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/171724 | |
dc.language.iso | eng | |
dc.subject | Health Sciences | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Nükleer Tıp | |
dc.subject | Radiology, Nuclear Medicine and Imaging | |
dc.subject | Oncology | |
dc.subject | Radiological and Ultrasound Technology | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | RADYOLOJİ, NÜKLEER TIP ve MEDİKAL GÖRÜNTÜLEME | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.title | 5-Year Survival Data of Durvalumab after Chemoradiotherapy for unresectable Stage III NSCLC - an Update from the PACIFIC Study | |
dc.type | Makale | |
dc.relation.journal | STRAHLENTHERAPIE UND ONKOLOGIE | |
dc.contributor.department | VIivantes Klinikum Neukolln , , | |
dc.identifier.volume | 197 | |
dc.contributor.firstauthorID | 2692289 | |